- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05841420
Gemcitabine Versus Reduced-dose Combination Chemotherapy in Fragile Patients With Non-resectable Pancreatic Cancer
A Randomized Phase II Study of Gemcitabine Versus Reduced-dose Combination Chemotherapy in Fragile Patients With Non-resectable Pancreatic Cancer
The aim of the study is to compare the efficacy and toxicity of full-dose Gemcitabine and reduced-dose combination chemotherapy in patients with non-resectable pancreatic cancer, who are unfit for full-dose combination chemotherapy.
The patients will be equally randomized to arm A or arm B:
Arm A: Full-dose single agent treatment with Gemcitabine 1000 mg/m2 weekly on days 1, 8,and 15 every 4 weeks.
Arm B: Reduced-dose (80%) combination-treatment with Gemcitabine plus Nab-Paclitaxel (Gemcitabine: 800 mg/m2 plus Nab-Paclitaxel: 100 mg/m2 on day 1, 8 and 15 every 4 weeks)
Progression-free survival, overall survival and response rate will be estimated for each group, as well as toxicity and quality of life will be prospectively registered.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
According to guidelines the recommended treatment for patients with non-resectable pancreatic cancer (PC) is combination chemotherapy, whereas old and/or fragile patients can be offered Gemcitabine monotherapy, if they are fit for treatment. Phase III trials show improved effect of combination chemotherapy compared to Gemcitabine, but these trials were restricted to fit patients younger than 75 years of age, as full-dose combination chemotherapy is more toxic.
Studies in colorectal cancer and a post-hoc analysis of Gemcitabine plus Nab-Paclitaxel in PC suggest that reduced-dose of combination chemotherapy may be more efficient in terms of progression-free survival and less toxic as compared to monotherapy in elderly and/or frail patients, but reduced start-dosing of GemNab is not currently labelled.
Moreover, a recent Danish register-based study showed that more use of combination chemotherapy at oncological departments was associated with improved outcome of patients with PC.
Elderly and frail patients with PC are in great need of better treatment results. Hence, a comparative study of reduced-dose combination chemotherapy is warranted and may be practice changing.
The aim of the study is to compare the efficacy and toxicity of full-dose Gemcitabine and reduced-dose combination chemotherapy in patients with non-resectable PC, who are unfit for full-dose combination chemotherapy.
The study is a national multicenter prospective randomized phase II trial, endorsed by the Danish Pancreas Cancer Group (DPCG). 98 patients with non-resectable PC, unfit for full-dose combination chemotherapy, but eligible for first-line chemotherapy, will be included.
The patients will be equally randomized to arm A or arm B:
Arm A: Full-dose single agent treatment with Gemcitabine 1000 mg/m2 weekly on days 1, 8 and 15 every 4 weeks.
Arm B: Reduced-dose (80%) combination-treatment with GemNab (Gemcitabine: 800 mg/m2 plus Nab-Paclitaxel: 100 mg/m2 on day 1, 8 and 15 every 4 weeks).
Progression-free survival, overall survival and response rate will be estimated for each group, as well as toxicity and quality of life will be prospectively registered.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Morten Ladekarl, Professor
- Phone Number: 0045+61399326
- Email: morten.ladekarl@rn.dk
Study Contact Backup
- Name: Louise Rasmussen, PhD
- Phone Number: 0045+30226432
- Email: loskr@rn.dk
Study Locations
-
-
-
Aalborg, Denmark, 9000
- Recruiting
- Department of Oncology, Aalborg University Hospital
-
Contact:
- Morten Ladekarl, MD, DMSci
- Phone Number: +45 97660545
- Email: morten.ladekarl@rn.dk
-
Contact:
- Anja Pagh, MD, PhD
- Phone Number: +45 97661417
- Email: a.pagh@rn.dk
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥ 18 years
- Adenocarcinoma of the pancreas, histopathologically or cytologically verified
- Non-resectable (locally advanced or metastatic) PC
- Patients unfit or not candidate for full-dose combination chemotherapy
- Patients eligible for full dose gemcitabine or reduced dose combination chemotherapy
- Performance status (PS) ≤2
- Measurable or non-measurable disease
- Adequate hematologic function defined as absolute neutrophil count (ANC) ≥1.5 x 10^9/l and platelets count ≥100x10^9/l within 2 weeks prior to enrollment
- Adequate organ function (bilirubin ≤1.5 x UNL (Upper Normal Limit) and eGFR (estimated Glomerular Filtration Rate) >50ml/min within 2 weeks prior to enrollment
- Toxicity of prior chemotherapy, including neurotoxicity, resolved to CTCAE <grade 2
- Oral and written informed consent must be obtained according to the local Ethics committee requirements
- Fertile patients must use adequate contraceptives
Exclusion Criteria:
- Patients eligible for downstaging/preoperative chemotherapy followed by resection or local ablation or irradiation
- Prior chemotherapy for PC (However, patients treated with adjuvant therapy with recurrence occurring more than 6 months after end of this treatment are eligible)
- Concurrent, non-curatively treated malignant neoplasm other than pancreatic adenocarcinoma
- Concurrent treatment with any other anti-cancer therapy
- Pregnant or breast-feeding patients
- Patients clearly intending to withdraw from the study if not randomized in the willing arm or patients who cannot be regularly followed up for psychological, social, familiar, or geographic reasons.
- Other condition or therapy, which in the investigator's opinion may pose a risk to the patient or interfere with the study objectives.
- Known allergy or intolerance to any of the drugs used in DPCG-01 (Gemcitabine, S1 or Nab-Paclitaxel)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: A: "Full dose single agent strategy"
Gemcitabine monotherapy, 1000 mg/m2 weekly on days 1, 8, and 15 every 4 weeks
|
Gemcitabine monotherapy, 1000 mg/m2 weekly on days 1, 8, and 15 every 4 weeks or gemcitabine: 800 mg/m2 on day 1, 8 and 15 every 4 weeks
Other Names:
|
Experimental: B: "Reduced dose (80%) combination-therapy strategy"
Nab-Paclitaxel: 100mg/m2 plus gemcitabine: 800 mg/m2 on day 1, 8 and 15 every 4 weeks
|
Gemcitabine monotherapy, 1000 mg/m2 weekly on days 1, 8, and 15 every 4 weeks or gemcitabine: 800 mg/m2 on day 1, 8 and 15 every 4 weeks
Other Names:
Nab-Paclitaxel: 100mg/m2 on day 1, 8 and 15 every 4 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PFS (Progression Free Survival)
Time Frame: 1 year from end of study accrual.
|
PFS is defined in the ITT population as the date of the randomization to the date of disease progression or date of death, whichever comes first.
The date of PD is the date of scan, if progression is found on a CT scan, or date of visit at which clinical progression is found.
PD at CT is defined according to RECIST version 1.1.
|
1 year from end of study accrual.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
OS (Overall Survival)
Time Frame: 1 year from end of study accrual.
|
OS is defined in the ITT population as the date of randomization to date of death of all causes.
|
1 year from end of study accrual.
|
RR (Response rate)
Time Frame: 1 year from end of study accrual.
|
In patients with measurable disease at baseline, RECIST version 1.1 will be used for evaluation of complete response (CR), partial response (PR), stable disease (SD) or PD.
ORR will be calculated as the percentage of patients with CR+PR of all patients with measurable disease, who received at least one treatment and were evaluated by at least one diagnostic CT scan.
|
1 year from end of study accrual.
|
Hospitalizations
Time Frame: Through study completion, an average of 6 months.
|
The total number of hospital admissions in a stationary unit with overnight stay from the start of treatment to the date of end of treatment will be assessed in the treated population.
If the patient is readmitted for the same reason within 3 days (e.g., after weekend leave), this is not counted as a separate admission.
The reasons for admission are registered as toxicity due to treatment or symptoms due to PC.
The sum of hospitalizations is calculated for each randomization arm for comparison.
|
Through study completion, an average of 6 months.
|
Quality of Life (QOL) assessed by EORTC QLQ-C30 at baseline and after 8, 16, and 24weeks
Time Frame: At baseline and at 8, 16, and 24 weeks.
|
QoL scores collected will be linearly transformed to a scale of 0 to 100.
Items will be grouped in health status scale (range 0 - 100, high is better), functional scales (range 0 - 100, high is better) and symptom scales (range 0 - 100, low is better).
Each scale is summarized by its mean, and standard deviation for the patients in the two treatment groups.
The difference in mean at 8, 16 and 24 weeks are compared with the baseline mean within in each treatment groups.
The difference in mean between the treatment groups are compared at baseline, 8, 16 and 12 weeks.
|
At baseline and at 8, 16, and 24 weeks.
|
Cumulative worst toxicity during treatment
Time Frame: From date of first treatment until 1 year from end of study treatment.
|
(Adverse events ≥ grade 3 according to CTCAE version 5.0).
All patients who have received 1 dose of chemotherapy will be calculated in the safety analyses.
Cumulative worst toxicities ≥CTC grade 3 in the treated population are registered for each arm separately for comparison.
|
From date of first treatment until 1 year from end of study treatment.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Morten Ladekarl, Professor, Aalborg Universitets Hospital, Department of Oncology
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Endocrine System Diseases
- Digestive System Neoplasms
- Endocrine Gland Neoplasms
- Pancreatic Diseases
- Pancreatic Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Paclitaxel
- Gemcitabine
Other Study ID Numbers
- DPCG-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreas Cancer
-
Washington University School of MedicineCompletedPancreatic Cancer | Pancreas Cancer | Pancreas Neoplasms | Cancer of Pancreas | Cancer of the PancreasUnited States
-
Joseph J. CullenNational Cancer Institute (NCI); National Institutes of Health (NIH); Holden... and other collaboratorsActive, not recruitingAdenocarcinoma | Pancreatic Neoplasms | Pancreas Cancer | Pancreas Neoplasms | Cancer of Pancreas | Cancer of the Pancreas | Neoplasms, PancreaticUnited States
-
Emory UniversityCompletedPancreas Cancer | Pancreas Neoplasms | Cancer of Pancreas | Cancer of the Pancreas | Neoplasms, PancreaticUnited States
-
Washington University School of MedicineNational Cancer Institute (NCI); BioMed Valley Discoveries, IncTerminatedPancreatic Cancer | Pancreas Cancer | Cancer of Pancreas | Cancer of the PancreasUnited States
-
National Cancer Institute (NCI)CompletedPancreatic Neoplasms | Pancreatic Cancer | Pancreas Cancer | Cancer of Pancreas | Cancer of the PancreasUnited States
-
BioXcel Therapeutics IncIQVIA BiotechWithdrawnPancreatic Cancer | Pancreas Cancer | Cancer of Pancreas | Cancer of the Pancreas | Neoplasms, PancreaticUnited States
-
Baylor Research InstituteUnknownPancreas Cancer | Localized Pancreas Cancer | Non-metastatic Pancreas CancerUnited States
-
AmgenTerminatedPancreatic Cancer | Pancreas Cancer | Cancer of Pancreas | Cancer of the Pancreas
-
Washington University School of MedicineTerminatedPancreatic Cancer | Pancreas Cancer | Cancer of Pancreas | Cancer of the PancreasUnited States
-
Newcastle-upon-Tyne Hospitals NHS TrustMedtronicCompletedPancreas Adenocarcinoma | Chronic Pancreatitis | Pancreas Cancer | Pancreas Neoplasm, BenignUnited Kingdom
Clinical Trials on Gemcitabine
-
AstraZenecaRecruitingBiliary Tract CancerFrance, Spain, Italy, Korea, Republic of, Japan, Germany, United States, Singapore
-
Sierra Oncology LLC - a GSK companyCompletedAdvanced Solid TumorsSpain, United Kingdom
-
University of Erlangen-Nürnberg Medical SchoolCompleted
-
Shenzhen University General HospitalNot yet recruiting
-
3D Medicines (Sichuan) Co., Ltd.Not yet recruitingBiliary Tract Neoplasms
-
Kansai Hepatobiliary Oncology GroupCompleted
-
Fifth Affiliated Hospital, Sun Yat-Sen UniversityRecruiting
-
3D Medicines (Sichuan) Co., Ltd.RecruitingBiliary Tract NeoplasmsChina
-
Yung NAQueen Mary Hospital, Hong Kong; Pamela Youde Nethersole Eastern HospitalRecruitingMuscle-Invasive Bladder Carcinoma | Muscle Invasive Bladder Urothelial CarcinomaHong Kong
-
Air Force Military Medical University, ChinaRecruiting